OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Casper Webers, Augusta Ortolan, Alexandre Sepriano, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 130-141
Open Access | Times Cited: 72
Casper Webers, Augusta Ortolan, Alexandre Sepriano, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 130-141
Open Access | Times Cited: 72
Showing 51-75 of 72 citing articles:
Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
Saad Ahmed, Rohan Isaac Yesudian, Hassan Ubaide, et al.
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 4
Open Access
Saad Ahmed, Rohan Isaac Yesudian, Hassan Ubaide, et al.
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 4
Open Access
Tumor necrosis factor-alpha inhibitors may increase the need for fine-needle aspiration cytology in axial spondyloarthritis patients
Zeynel Abidin Sayıner, Hayriye Sultan Munis, İpek Köroğlu, et al.
Revista da Associação Médica Brasileira (2024) Vol. 70, Iss. 12
Open Access
Zeynel Abidin Sayıner, Hayriye Sultan Munis, İpek Köroğlu, et al.
Revista da Associação Médica Brasileira (2024) Vol. 70, Iss. 12
Open Access
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis
Atul Deodhar, Servet Akar, Jeffrey R. Curtis, et al.
Advances in Rheumatology (2024) Vol. 64, Iss. 1
Open Access
Atul Deodhar, Servet Akar, Jeffrey R. Curtis, et al.
Advances in Rheumatology (2024) Vol. 64, Iss. 1
Open Access
The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis
Bora Nam, Tae‐Hwan Kim
Immunotherapy (2024) Vol. 16, Iss. 9, pp. 569-580
Closed Access
Bora Nam, Tae‐Hwan Kim
Immunotherapy (2024) Vol. 16, Iss. 9, pp. 569-580
Closed Access
Early identification of golimumab-treated patients with higher likelihood of long-term retention
Alicia García-Dorta, Enrique González‐Dávila, Marta Sánchez‐Jareño, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Alicia García-Dorta, Enrique González‐Dávila, Marta Sánchez‐Jareño, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Martín Rudwaleit, Atul Deodhar, Lars Bauer, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003884-e003884
Open Access
Martín Rudwaleit, Atul Deodhar, Lars Bauer, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003884-e003884
Open Access
An update in the pharmacological management of axial spondyloarthritis
Kyaw Oo, Saad Ahmed, Lily Snell, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 8, pp. 957-971
Closed Access
Kyaw Oo, Saad Ahmed, Lily Snell, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 8, pp. 957-971
Closed Access
Long-term association between physical activity and global functioning in patients with axial spondyloarthritis: results of a two-year prospective study
Kwi Young Kang, SY Park, TH Chung
Scandinavian Journal of Rheumatology (2024), pp. 1-8
Closed Access
Kwi Young Kang, SY Park, TH Chung
Scandinavian Journal of Rheumatology (2024), pp. 1-8
Closed Access
Comparative real-world retention rate and safety of Biosimilar IBI303 versus Humira in Ankylosing Spondylitis
Xiao‐Gui Cheng, Zhongchao Fu, Jiang Liu, et al.
Research Square (Research Square) (2024)
Open Access
Xiao‐Gui Cheng, Zhongchao Fu, Jiang Liu, et al.
Research Square (Research Square) (2024)
Open Access
Comparing Treatment Guidelines for Axial Spondyloarthritis
Enrique R. Soriano, Victoria Navarro‐Compán, Wilson Bautista‐Molano, et al.
JCR Journal of Clinical Rheumatology (2024)
Closed Access
Enrique R. Soriano, Victoria Navarro‐Compán, Wilson Bautista‐Molano, et al.
JCR Journal of Clinical Rheumatology (2024)
Closed Access
Complement proteins in axial spondyloarthritis: associations with disease activity and TNFi treatment response in a multicenter randomised controlled trial
Clara Mistegård Jørgensen, Anne Troldborg, Murat Torğutalp, et al.
Rheumatology Advances in Practice (2024) Vol. 9, Iss. 1
Open Access
Clara Mistegård Jørgensen, Anne Troldborg, Murat Torğutalp, et al.
Rheumatology Advances in Practice (2024) Vol. 9, Iss. 1
Open Access
Knowledge mapping of biological disease-modifying anti-rheumatic drugs for axial spondyloarthritis: a bibliometric study
Qian He, Jiaqi Chen, Xin-bo Yu, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 8, pp. 1999-2011
Closed Access | Times Cited: 1
Qian He, Jiaqi Chen, Xin-bo Yu, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 8, pp. 1999-2011
Closed Access | Times Cited: 1
The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
Jie Chang, Gang Wang
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
Jie Chang, Gang Wang
Research Square (Research Square) (2023)
Open Access | Times Cited: 1
A Move Toward Precision: Innovations in Measuring Spinal Mobility in Axial Spondyloarthritis
Joerg Ermann
The Journal of Rheumatology (2023) Vol. 50, Iss. 11, pp. 1362-1363
Open Access | Times Cited: 1
Joerg Ermann
The Journal of Rheumatology (2023) Vol. 50, Iss. 11, pp. 1362-1363
Open Access | Times Cited: 1
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease
Marina Yamashita, Mamiko Takayasu, Hiroshi Maruyama, et al.
Medicina (2023) Vol. 59, Iss. 11, pp. 2014-2014
Open Access | Times Cited: 1
Marina Yamashita, Mamiko Takayasu, Hiroshi Maruyama, et al.
Medicina (2023) Vol. 59, Iss. 11, pp. 2014-2014
Open Access | Times Cited: 1
How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?
Ivan Foeldvari, Harry Petrushkin
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 267-276
Closed Access | Times Cited: 1
Ivan Foeldvari, Harry Petrushkin
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 267-276
Closed Access | Times Cited: 1
Ankylosing Spondylitis
Eleftherios Pelechas, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, et al.
Springer eBooks (2023), pp. 173-194
Closed Access | Times Cited: 1
Eleftherios Pelechas, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, et al.
Springer eBooks (2023), pp. 173-194
Closed Access | Times Cited: 1
Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis: A review of the literature and discussion on current practice
Casper Webers, Elena Nikiphorou, Annelies Boonen, et al.
Joint Bone Spine (2022) Vol. 90, Iss. 1, pp. 105482-105482
Open Access | Times Cited: 2
Casper Webers, Elena Nikiphorou, Annelies Boonen, et al.
Joint Bone Spine (2022) Vol. 90, Iss. 1, pp. 105482-105482
Open Access | Times Cited: 2
Décroissance ou arrêt des traitements de fond biologiques dans la spondyloarthrite axiale : revue de la littérature
Casper Webers, Elena Nikiphorou, Annelies Boonen, et al.
Revue du Rhumatisme (2023) Vol. 90, Iss. 3, pp. 291-304
Open Access
Casper Webers, Elena Nikiphorou, Annelies Boonen, et al.
Revue du Rhumatisme (2023) Vol. 90, Iss. 3, pp. 291-304
Open Access
Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process
Rosario García‐Vicuña, Xavier Juanola, Victoria Navarro‐Compán, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 5, pp. 1215-1240
Open Access
Rosario García‐Vicuña, Xavier Juanola, Victoria Navarro‐Compán, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 5, pp. 1215-1240
Open Access
To taper or not to taper biological disease-modifying antirheumatic drugs in axial spondyloarthritis anno 2023: That is the question
Zuzanna Łukasik, Philippe Carron, Casper Webers
Best Practice & Research Clinical Rheumatology (2023) Vol. 37, Iss. 3, pp. 101869-101869
Open Access
Zuzanna Łukasik, Philippe Carron, Casper Webers
Best Practice & Research Clinical Rheumatology (2023) Vol. 37, Iss. 3, pp. 101869-101869
Open Access
Aktuelle Leitlinien der axialen Spondyloarthritis für Praxis und Klinik
Iuliia Kononenko, David Kiefer, Xenofon Baraliakos, et al.
Arthritis und Rheuma (2023) Vol. 43, Iss. 05, pp. 307-314
Closed Access
Iuliia Kononenko, David Kiefer, Xenofon Baraliakos, et al.
Arthritis und Rheuma (2023) Vol. 43, Iss. 05, pp. 307-314
Closed Access
Treatment of axial spondyloarthritis patients with biologic disease-modifying anti-rheumatic drugs in 2022 - data from the Romanian Registry of Rheumatic Diseases
Laura Muntean, R. Ionescu, Corina Mogoșan, et al.
Romanian Journal of Rheumatology (2023) Vol. 32, Iss. 4, pp. 153-160
Open Access
Laura Muntean, R. Ionescu, Corina Mogoșan, et al.
Romanian Journal of Rheumatology (2023) Vol. 32, Iss. 4, pp. 153-160
Open Access
Psoriatic Arthritis
Eleftherios Pelechas, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, et al.
Springer eBooks (2023), pp. 195-225
Closed Access
Eleftherios Pelechas, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, et al.
Springer eBooks (2023), pp. 195-225
Closed Access
